Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
450 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06033482 | The Possible Range of No.12a Lymph Node Dissection of Locally Advanced Gastric Cancer | unknown | — | 100 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05864755 | HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER |
| 1 |
| Aug 23, 2023 |
| clinicaltrials |
| NCT05997147 | A Preoperative Model to Predict the Lymphovascular Invasion in Pancreatic Ductal Adenocarcinoma | unknown | — | 1,009 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05975944 | Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 49 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05974059 | Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03950154 | Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer | unknown | Phase 3 | 198 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05942573 | Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial | unknown | Phase 2 | 107 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05828875 | A Multicenter, Cross-sectional Study on the Quality of Life in Long-term Survival Esophageal Cancer Patients After Radical Radiochemotherapy/Radiotherapy | unknown | — | 1,000 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 7, 2023 | clinicaltrials |
| NCT04267549 | Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer | unknown | Phase 2 | 47 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT05890287 | A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy | recruiting | N/A | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT05885776 | Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI Research(PYTHON) | unknown | Phase 2 | 48 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05874778 | A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission | unknown | Phase 2 | 108 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 25, 2023 | clinicaltrials |
| NCT05872841 | H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis | unknown | Phase 2 | 38 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 24, 2023 | clinicaltrials |
| NCT05871918 | A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer | unknown | Phase 3 | 832 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05854030 | Serum Exosomal miRNA Predicting the Therapeutic Efficiency in Lung Squamous Carcinoma | unknown | — | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT05853172 | Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05842018 | Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors) | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 3, 2023 | clinicaltrials |
| NCT05821361 | HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT04936750 | A One-arm, Prospective Study Comparing the Effects of Different Body Composition on the Survival of Patients Undergoing Radical Concurrent Chemoradiotherapy for Esophageal Cancer | unknown | — | 120 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT04733417 | A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer. | unknown | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05812495 | Minimally Invasive Intrathoracic Esophagogastric Side to Side Anastomosis vs. End to Side Anastomosis | unknown | N/A | 402 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT04836520 | SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer. | completed | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT04389177 | Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001) | unknown | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05806671 | Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05781633 | The Efficacy and Safety of Eutideron, Etoposide, and Bevacizumab in Patients With Brain Metastases From Breast Cancer. | unknown | N/A | 43 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT05616390 | Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05778149 | Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation | not yet recruiting | Phase 2 | 47 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 21, 2023 | clinicaltrials |
| NCT04199832 | To Compare the Effect of Different Nutritional Pathways on Improving Nutritional Status of Esophageal Cancer Patients Undergoing Chemoradiotherapy | completed | — | 156 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04745130 | Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti) | unknown | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05723978 | Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study. | completed | — | 520 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05720533 | Disitamab Vedotin Combined With Sintilimab as First-line Treatment of Elderly Patients With Gastric Cancer | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Feb 9, 2023 | clinicaltrials |
| NCT05029973 | HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05025033 | Chemotherapy Combined With Apatinib and PD-1 Antibody | completed | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT05686434 | Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR) | recruiting | Phase 2 | 65 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05683704 | Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT05678933 | AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH | enrolling by invitation | Phase 3 | 200 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT05679050 | Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT05672537 | Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk | unknown | Phase 2 | 70 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT05651672 | Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations | recruiting | Phase 2 | 100 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05644392 | A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours | unknown | Phase 1 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05637268 | Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 23 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 5, 2022 | clinicaltrials |
| NCT05627414 | Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 25, 2022 | clinicaltrials |
| NCT05627427 | Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT05620498 | Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC. | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05595590 | Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05596435 | Early Detection of Pancreatic Cancer | unknown | — | 496 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05582109 | Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Oct 17, 2022 | clinicaltrials |
| NCT05560308 | Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy | unknown | N/A | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Oct 3, 2022 | clinicaltrials |
| NCT05085626 | Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05295043 | Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer | unknown | N/A | 500 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Sep 29, 2022 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials